Eddie Pharmaceuticals: Revenue in 2025 increased by 72.57%, and the loss margin narrowed significantly.

Eddie Pharmaceutical announced that it is expected to achieve a revenue of approximately 721.01 million yuan in 2025, an increase of about 72.57% year-on-year. Among them, the revenue from innovative HIV drugs is expected to be 285.31 million yuan, a year-on-year increase of 90.34%, and the revenue from Nanda Pharmaceutical is expected to be 299.83 million yuan, a year-on-year increase of 227.38% on a consolidated basis. The net profit attributable to the owners of the parent company is expected to be approximately -16 to -24 million yuan, with a year-on-year decrease in loss of about 88.67% to 83.00%; the non-GAAP net profit is estimated to be approximately -17.2 to -25.2 million yuan, with a year-on-year decrease in loss of about 88.41% to 83.02%. This is mainly due to an increase in gross profit from main business operations and an increase in sales expenses.